3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
47
Lung Neoplasms
23
Carcinoma, Hepatocellular
23
Small Cell Lung Carcinoma
16
Cholangiocarcinoma
10
Breast Neoplasms
10
Urinary Bladder Neoplasms
9
Biliary Tract Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Liver Neoplasms
8
Pancreatic Neoplasms
6
Carcinoma
6
Endometrial Neoplasms
5
Triple Negative Breast Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Transitional Cell
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Bile Duct Neoplasms
3
Adenocarcinoma
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Respiratory Tract Neoplasms
2
Pathologic Complete Response
2
Oropharyngeal Neoplasms
2
Neoplasms by Histologic Type
2
Interventions
Cyclophosphamide
5
Rituximab
4
Vincristine
3
Prednisone
3
Doxorubicin
3
Etoposide
2
venetoclax
1
pembrolizumab
1
liposomal doxorubicin
1
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
etoposide phosphate
1
acalabrutinib
1
Zidovudine
1
Whole-Body Irradiation
1
Valganciclovir
1
Tacrolimus
1
Sirolimus
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Nivolumab
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Interferon-alpha
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
CLR1404
1
CA-4948
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
durvalumab
×
90 days
×
Clear all
No trials found.